DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Saethre-Chotzen syndrome — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSaethre-Chotzen syndrome maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for saethre-chotzen syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor receptor 3 (FGFR3) — FGFR3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4K33 · 2.3405 Å · ligand PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER (ACP). Experimental structure, not a prediction.
What the evidence adds up to
Of 11 patients clinically diagnosed with Saethre-Chotzen syndrome, 9 (82%) had detectable genetic changes in either FGFR3 or TWIST. Four carried the FGFR3 P250R mutation, three had novel mutations in the coding region of TWIST, and two had a deletion of one copy of the entire TWIST gene. Patients with the whole-gene deletion showed developmental delay, which distinguished them from those with intragenic TWIST mutations. No mutations were found in four patients with craniosynostosis but no clear diagnosis. A separate cytogenetic study reported a father and daughter with an apparently balanced t(7;10)(p21.2;q21.2) translocation who both had Saethre-Chotzen syndrome, supporting localisation of the gene to 7p21.2.
A 1972 report described five affected individuals across four generations. Serial roentgencephalometric data showed similarity in skull form among affected individuals. Head circumference was misleading as an index of cranial growth or intellectual potential in affected adults, whereas cranial capacity measured by the modulus was more reliable.
Twenty-nine patients with Saethre-Chotzen syndrome had audiologic records reviewed. Mean age at first evaluation was 6.7 years (range 0.7 to 24.5). Seventeen patients (59%) had at least one abnormal audiogram; in 15 the deficit was mild. Eight patients showed sensorineural hearing loss, but five of those cases later resolved and had been mischaracterised. Six patients had conductive hearing loss on at least one examination; follow-up in four showed normal hearing. One patient had mixed hearing loss on consecutive audiograms. Twenty-one patients (72%) had normal hearing on their last audiogram. Most hearing loss was mild, correlated with middle ear abnormality and eustachian tube dysfunction, and typically resolved.
No drug treatment is mentioned in any of these abstracts. What is missing for any potential drug-repurposing effort is a molecular target validated in Saethre-Chotzen syndrome, a clinical trial design that accounts for the genetic heterogeneity (TWIST mutations, TWIST deletions, FGFR3 P250R), and funding for preclinical work in relevant models. Patient stratification by genotype and by the presence or absence of developmental delay would be necessary before any intervention could be tested.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 2002 · 85 citations
Genetic analysis of patients with the Saethre‐Chotzen phenotype
AbstractSaethre-Chotzen syndrome is a common craniosynostosis syndrome characterized by craniofacial and limb anomalies. Intragenic mutations of the TWIST gene within 7p21 have been identified as a cause of this disorder. There is phenotypic overlap with other craniosynostosis syndromes, and intragenic mutations in FGFR2 (fibroblast growth factor receptor 2) and FGFR3 (fibroblast growth factor receptor 3) have been demonstrated in the other conditions. Furthermore, complete gene deletions of TWIST have also been found in a significant proportion of patients with Saethre-Chotzen syndrome. We investigated 11 patients clinically identified as having the Saethre-Chotzen phenotype and 4 patients with craniosynostosis but without a clear diagnosis. Of the patients with the Saethre-Chotzen phenotype, four were found to carry the FGFR3 P250R mutation, three were found to be heterozygous for three different novel mutations in the coding region of TWIST, and two were found to have a deletion of one copy of the entire TWIST gene. Developmental delay was a distinguishing feature of the patients with deletions, compared to patients with intragenic mutations of TWIST, in agreement with the results of Johnson et al. [1998: Am J Hum Genet 63:1282-1293]. No mutations were found for the four patients with craniosynostosis without a clear diagnosis. Therefore, 9 of our 11 patients (82%) with the Saethre-Chotzen phenotype had detectable genetic changes in FGFR3 or TWIST. We propose that initial screening for the FGFR3 P250R mutation, followed by sequencing of TWIST and then fluorescence in situ hybridization (FISH) for deletion detection of TWIST, is sufficient to detect mutations in > 80% of patients with the Saethre-Chotzen phenotype.
American Journal of Medical Genetics · 1993 · 46 citations
Cytogenetic evidence that the Saethre‐Chotzen gene maps to 7p21.2
AbstractEvidence for the location of the Saethre-Chotzen acrocephalosyndactyly mutation on 7p21-22 is based on genetic linkage studies in families segregating for this autosomal dominant disorder. Linkage studies were guided by several reports of chromosome deletions in this region giving rise to craniosynostosis and some other manifestations of Saethre-Chotzen syndrome. We report on a family where a father and daughter carry an apparently balanced t(7;10)(p21.2;q21.2) translocation (de novo in the father) and have the Saethre-Chotzen syndrome. These observations support the localization of the Saethre-Chotzen gene to 7p21.2.
AbstractAbstract Five individuals in four generations affected with the Saethre‐Chotzen syndrome are reported. Serial roentgencephalometric data obtained pre‐ and postoperatively on the proband were compared with similar measurements on the affected mother and maternal uncle, both of whom had not had operative corrections. Similarity in skull form among the affected individuals was demonstrated. Head circumference, as an index of cranial growth or intracranial capacity, was misleading in assessing the intellectual potential of the affected adults. In contrast, cranial capacity, as measured by the modulus, was found to be more reliable.
Plastic & Reconstructive Surgery · 2011 · 12 citations
Audiologic Findings in Saethre-Chotzen Syndrome
AbstractBACKGROUND: Hearing loss has been described in Apert syndrome but is poorly documented in other craniosynostosis disorders. METHODS: The authors retrospectively reviewed the audiologic and otologic records of patients with Saethre-Chotzen syndrome to define the incidence, type, and extent of hearing loss. Only patients with documented audiologic examinations were included. Hearing loss was categorized by American Speech-Language-Hearing Association guidelines (i.e., mild, 26 to 40 dB; moderate, 41 to 55 dB; moderate/severe, 56 to 70 dB; severe, 71 to 90 dB; and profound, >90 dB). RESULTS: Twenty-nine patients met inclusion criteria. Mean age at initial audiologic evaluation was 6.7 years (range, 0.7 to 24.5 years). Seventeen patients (59 percent) had at least one abnormal audiogram; in 15 patients, the deficit was mild. Eight patients demonstrated sensorineural hearing loss. Five cases resolved and, thus, had been mischaracterized. Six patients had conductive hearing loss on at least one examination; follow-up testing in four patients revealed normal hearing. Two patients had unspecified hearing loss by sound field method. One patient had mixed hearing loss on consecutive audiograms. Twenty-one patients (72 percent) had normal hearing on their last audiogram. CONCLUSIONS: Most patients with Saethre-Chotzen syndrome had hearing loss at some point during childhood. This was typically mild and correlated with middle ear abnormality and eustachian tube dysfunction. Usually, the hearing deficit resolved. Early mischaracterization of mixed hearing loss or conductive hearing loss as sensorineural hearing loss was common.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
